Why does AbbVie want to acquire Apogee Therapeutics?

AbbVie aims to strengthen its portfolio in immunology and respiratory treatments, where Apogee has promising programs.

How did the announcement affect AbbVie and Apogee Therapeutics stocks?

Apogee Therapeutics' stock surged over 30%, while AbbVie's shares experienced minor fluctuations.

Is the deal expected to face regulatory hurdles?

The deal will likely face antitrust reviews, but due to limited overlap, approvals are expected.

AbbVie to Acquire Apogee Therapeutics in All-Cash Deal

AbbVie (ABBV) announced an all-cash acquisition offer for Apogee Therapeutics, causing a sharp rise in the latter's stock. The financial terms have not yet been disclosed.

June 23, 2026

2 min read

Source: Motley Fool

AbbVie (ABBV) has announced an all-cash acquisition offer for Apogee Therapeutics, according to reports from Motley Fool on June 22, 2026. The announcement sent Apogee Therapeutics' stock surging during the trading session.

Deal Details

AbbVie has not yet disclosed the total deal value or the cash price per share. Further financial details are expected in an upcoming official statement. Sources indicate the transaction will be entirely cash-based.

Rationale Behind the Deal

AbbVie aims to strengthen its biopharmaceutical portfolio, particularly in immunology and respiratory treatments, which are Apogee's focus areas. The acquisition is expected to accelerate AbbVie's R&D programs.

Regulatory Challenges

The deal will likely face antitrust reviews in the U.S. and Europe. However, given the lack of significant product overlap, regulatory approvals are expected without major hurdles.

Impact on Stocks

Apogee Therapeutics' stock jumped over 30% following the announcement, while AbbVie's shares experienced minor fluctuations. Apogee's stock is expected to trade near the offer price until the deal closes.

Frequently Asked Questions

AbbVie has not yet disclosed the cash price per share or the total deal value. Details are expected to be announced soon.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.